Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Early Identification of Refractory/Relapsed Diffuse Large B Cell Lymphoma with Serial Ctdna Sampling

Ryan N Rys, Elie Ritch, Christopher Rushton, Abdelrahman Ahmed, Eugene Brailovski, Christian Steidl, David W. Scott, Ryan Morin, Nathalie A. Johnson

Blood (2023) 142 (Supplement 1): 2996.

https://doi.org/10.1182/blood-2023-190649

Published: 2023

Journal Articles

Large-Scale Genomic Analysis of Mutational Hotspots in Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma

Manuela Cruz, Kostiantyn Dreval, Prasath Pararajalingam, Laura Hilton, Jasper Wong, Christopher Rushton, Ryan Morin

Blood (2023) 142 (Supplement 1): 2992.

https://doi.org/10.1182/blood-2023-185914

Published: 2023

Journal Articles

Characterization of DLBCL with a PMBL gene expression signature

Blood (2021) 138 (2): 136–148.

https://doi.org/10.1182/blood.2020007683

Published: 2021

Includes: Supplemental data

Journal Articles

Nfkbiz 3′ UTR Mutations Confer Selective Growth Advantage and Affect Drug Response in Diffuse Large B-Cell Lymphoma

Sarah E Arthur, BSc, Nicole Thomas, BSc, Christopher Rushton, BSc, Jeffrey Tang, Miguel Alcaide, PhD, Shannon Healy, PhD, Adele Telenius, Anja Mottok, MD PhD, David W. Scott, MBChB, PhD, Christian Steidl, MD, Ryan D Morin, PhDBSc,MSc

Blood (2020) 136 (Supplement 1): 31.

https://doi.org/10.1182/blood-2020-137700

Published: 2020

Journal Articles

The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-142871

Published: 2020

Journal Articles

Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing

Blood (2020) 136 (5): 572–584.

https://doi.org/10.1182/blood.2019002385

Published: 2020

Includes: Supplemental data

Journal Articles

Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP

Blood (2019) 134 (Supplement_1): 921.

https://doi.org/10.1182/blood-2019-127399

Published: 2019

Journal Articles

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Michael D. Jain, MD PhD, Anca Prica, MD, Ryan D. Morin, PhD, Vishal Kukreti, MD, Robert Kridel, MDMPH,PhD, Rob C. Laister, PhD, Li Meng, Christopher Rushton, Miguel Alcaide, Rashmi S. Goswami, MD PhD, Jan Delabie, MD PhD, Jessica Weiss, Tony Panzarella, M.Sc., P.Stat, Michael Crump, MD, David W. Scott, MBChB, PhD, John Kuruvilla, MD

Blood (2019) 134 (Supplement_1): 2027.

https://doi.org/10.1182/blood-2019-131818

Published: 2019

Journal Articles

NFKBIZ 3′ UTR Mutations Confer Selective Growth Advantage and Activate Genes with Therapeutic Implications in Diffuse Large B-Cell Lymphoma

Sarah E Arthur, BSc, Nicole Thomas, BSc, Christopher Rushton, BSc, Miguel Alcaide, PhD, Shannon Healy, PhD, Anja Mottok, MD PhD, David W. Scott, MBChB, PhD, Christian Steidl, MD, Ryan D. Morin, PhD

Blood (2019) 134 (Supplement_1): 296.

https://doi.org/10.1182/blood-2019-127421

Published: 2019

Journal Articles

Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1478.

https://doi.org/10.1182/blood-2019-129136

Published: 2019

Journal Articles

CD20 Is an Unstable Target in Primary-Refractory High-Grade Lymphomas

Ryan N Rys, BSc, BA, Dominique Geoffrion, BSc, Christopher Rushton, BSc, Miguel Alcaide, PhD, Raoul Santiago, MDMSc, Koren Kathleen Mann, PhD, Svetlana Dmitrienko, MD PhD, Tina Petrogiannis-Haliotis, MD PhD, Sarit Assouline, MD, Ryan D. Morin, PhD, Nathalie Johnson, MD

Blood (2019) 134 (Supplement_1): 1608.

https://doi.org/10.1182/blood-2019-127129

Published: 2019

Journal Articles

Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma

Blood (2019) 134 (10): 802–813.

https://doi.org/10.1182/blood.2019001126

Published: 2019

Includes: Supplemental data

Journal Articles

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Michael D. Jain, MD PhD, Ryan D. Morin, PhD BSc, MSc, Anca Prica, MD, Vishal Kukreti, MD, Robert Kridel, PhD MD, Rob C. Laister, PhD, Li Meng, Christopher Rushton, BSc, Miguel Alcaide, PhD, Rashmi S. Goswami, BSc, MD PhD FRCPC, Jan M.A. Delabie, MD PhD, Jessica Weiss, Tony Panzarella, M.Sc., P.Stat, Michael Crump, MD, David W. Scott, PhD MD, FRACP, FRCPA, John Kuruvilla, MD

Blood (2018) 132 (Supplement 1): 4610.

https://doi.org/10.1182/blood-2018-99-117333

Published: 2018

Journal Articles

Functional Investigation of the Gene NFKBIZ and the Impact of 3'UTR Mutations in Diffuse Large B-Cell Lymphoma

Sarah E Arthur, BSc, Anja Mottok, MD PhD, Miguel Alcaide, PhD, Christopher Rushton, BSc, Bruno M. Grande, BSc, Daisuke Ennishi, MDPhD, Jordan Davidson, BSc, Kevin R Bushell, BSc, MSc, Randy D. Gascoyne, MD, Marco A Marra, PhD, Joseph M Connors, MD, Gregg B Morin, PhD, David W. Scott, MD PhD FRACP, FRCPA, Christian Steidl, MD, Ryan D. Morin, PhDBSc,MSc

Blood (2017) 130 (Supplement 1): 1228.

https://doi.org/10.1182/blood.V130.Suppl_1.1228.1228

Published: 2017

NARROW

Early Identification of Refractory/Relapsed Diffuse Large B Cell Lymphoma with Serial Ctdna Sampling

Large-Scale Genomic Analysis of Mutational Hotspots in Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma

Characterization of DLBCL with a PMBL gene expression signature

Nfkbiz 3′ UTR Mutations Confer Selective Growth Advantage and Affect Drug Response in Diffuse Large B-Cell Lymphoma

The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing

Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

NFKBIZ 3′ UTR Mutations Confer Selective Growth Advantage and Activate Genes with Therapeutic Implications in Diffuse Large B-Cell Lymphoma

Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma

CD20 Is an Unstable Target in Primary-Refractory High-Grade Lymphomas

Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Functional Investigation of the Gene NFKBIZ and the Impact of 3'UTR Mutations in Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only